These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 21208197

  • 1. Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker?
    Carmona O, Masuet C, Santiago O, Alía P, Moral E, Alonso-Magdalena L, Casado V, Arbizu T.
    Acta Neurol Scand; 2011 Oct; 124(4):258-63. PubMed ID: 21208197
    [Abstract] [Full Text] [Related]

  • 2. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis.
    Portaccio E, Goretti B, Zipoli V, Nacmias B, Stromillo ML, Bartolozzi ML, Siracusa G, Guidi L, Federico A, Sorbi S, De Stefano N, Amato MP.
    Mult Scler; 2009 Dec; 15(12):1489-94. PubMed ID: 19965518
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype.
    Bracco L, Piccini C, Baccini M, Bessi V, Biancucci F, Nacmias B, Bagnoli S, Sorbi S.
    Dement Geriatr Cogn Disord; 2007 Jan; 24(6):483-91. PubMed ID: 18025782
    [Abstract] [Full Text] [Related]

  • 13. Neuropsychological testing and event-related potentials in the assessment of cognitive performance in the patients with multiple sclerosis--a pilot study.
    Pokryszko-Dragan A, Zagrajek M, Slotwinski K, Gruszka E, Bilinska M, Podemski R.
    Clin Neurol Neurosurg; 2009 Jul; 111(6):503-6. PubMed ID: 19233546
    [Abstract] [Full Text] [Related]

  • 14. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.
    Knopman DS, Mosley TH, Catellier DJ, Coker LH, Atherosclerosis Risk in Communities Study Brain MRI Study.
    Alzheimers Dement; 2009 May; 5(3):207-14. PubMed ID: 19362884
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
    Martins CA, Oulhaj A, de Jager CA, Williams JH.
    Neurology; 2005 Dec 27; 65(12):1888-93. PubMed ID: 16380608
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
    Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP, Copaxone Study Group.
    J Neurol Sci; 2007 Apr 15; 255(1-2):57-63. PubMed ID: 17331542
    [Abstract] [Full Text] [Related]

  • 20. Cognitive impairment in Alzheimer's disease is modified by APOE genotype.
    van der Vlies AE, Pijnenburg YA, Koene T, Klein M, Kok A, Scheltens P, van der Flier WM.
    Dement Geriatr Cogn Disord; 2007 Apr 15; 24(2):98-103. PubMed ID: 17596691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.